推荐产品
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D -80 to -90°, c = 1.0 in ethanol
顏色
white to beige
溶解度
DMSO: 2 mg/mL, clear
儲存溫度
−20°C
InChI
1S/C14H21NO3S/c1-10(2)9-12-5-7-13(8-6-12)11(3)14(16)15-19(4,17)18/h5-8,10-11H,9H2,1-4H3,(H,15,16)
InChI 密鑰
KQDRVXQXKZXMHP-UHFFFAOYSA-N
生化／生理作用
Reparixin is a noncompetitive allosteric inhibitor of the inflammatory CXCL8 (IL-8) chemokine receptors CXCR1 and CXCR2 with IC50 values of 1 nM for CXCR1 and 100 nM for CXCR2. It is believed to prevent receptor signaling by locking CXCR1/R2 in an inactive conformation. Reparixin has been studied to prevent ischaemia-reperfusion injury and inflammation and is clinical trials for triple negative breast cancer and to prevent injury occurring after pancreatic islet transplantation.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Anne F Schott et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(18), 5358-5365 (2017-05-26)
Purpose: Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational allosteric inhibitor of chemokine receptors 1 and 2 (CXCR1/2), and demonstrates activity against BCSCs in human breast
P Opfermann et al.
Clinical and experimental immunology, 180(1), 131-142 (2014-11-18)
Reparixin, a CXCR 1/2 antagonist, has been shown to mitigate ischaemia-reperfusion injury (IRI) in various organ systems in animals, but data in humans are scarce. The aim of this double-blinded, placebo-controlled pilot study was to evaluate the safety and efficacy
N C Bergenhem et al.
Biochemical genetics, 30(5-6), 279-287 (1992-06-01)
Two, electrophoretically distinct, forms of carbonic anhydrase I (CA Ia and CA Ib) are found at high polymorphic frequencies in red cells of natural populations of pigtail macaques, Macaca nemestrina, from southeast Asia. By use of the polymerase chain reaction
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门